Abstract:
Objective This study aimed to determine the correlation between liver fimction damage caused by chemotherapy in lung cancer patients with or without hepatitis B infection, and the differences between the reactivating effect of hepatitis B virus (HBV) caused by chemotherapy with or without prophylactic antivirus treatment.
Methods A total of 636 lung cancer patients in the Cancer Center of Sun Yat-Sen University from January 2008 to December 2009 were investigated retrospectively. The post-chemotherapy liver damage situations of 466 HBsAg-negative and 170 HBsAg-positive patients were compared. HBV-reactivated hepatitis was analyzed in the HBsAg-positive _patients, including 33 with and 43 without prophylactic antivirus treatment before and after chemotherapy.
Results The incidence of liver function impairment after chemotherapy was 29.4 % (50 / 170) in the HBsAg-positive patients, and 15.2 % (71 / 466) in the lib sAg-negative patients. The difference was statistically significant (P < 0.001). In the HBsAg-positive group, the HBV reactivation rate was 3.0 % (1 / 33) in the patients given prophylactic lamivudine, and 20.9 % (9 / 43) in the patients not given prophylactic antivirus treatment. The difference between these two groups was also statistically significant (P = 0.022).
Conclusion HBsAg-positive lung cancer patients are more likely to have liver function impairment than I-IBsAg-negative patients. Prophylactic antivirus treatment with the nucleoside analog lamivudine can significantly reduce the occurrence of HBV-reactivated hepatitis after chemotherapy in lung cancer patients. The results are worthy of verification by future studies.
下载: